home / stock / celu / celu news

CELU News and Press, Celularity Inc. From 04/05/23

Stock Information
Company Name: Celularity Inc.
Stock Symbol: CELU
Market: NASDAQ
Website: celularity.com
Menu
CELU CELU Quote CELU Short CELU News CELU Articles CELU Message Board
Get CELU Alerts

News, Short Squeeze, Breakout and More Instantly...
CELU - Celularity announces $6M registered direct offering

2023-04-05 09:39:12 ET Celularity ( NASDAQ: CELU ) has entered into a definitive agreement with an institutional investor for the purchase and sale of 9.23M shares of its Class A common stock and warrants up to 9.23M shares at a combined purchase price of $0.65/share. The ...
CELU - Celularity Inc. Announces $6 Million Registered Direct Offering

FLORHAM PARK, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a singl...

CELU - Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual ...

CELU - Penny Stocks To Buy? 4 To Watch Now After Big News This Week

2023-04-03 12:52:16 ET When searching for penny stocks to buy or watch, it’s important to focus on catalysts. Penny stocks , which are stocks priced under $5 per share, often attract small and new investors. However, investing in these stocks comes with inherent risks. So it ...
CELU - Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity's Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA's Center For Devices And Radiological Health

Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of the product Celularity intends to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) in early 20...

CELU - Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt

AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt Product distribution agreement opens access to Celularity’s Halal-Certified regenerative medicines...

CELU - Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devi

Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix Celularity to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) This press release corrects a...
CELU - Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Healt

Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix Celularity to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) FLORHAM PARK, N.J., Feb. 01, ...

CELU - Celularity falls as Morgan Stanley downgrades after strategic update

Celularity ( NASDAQ: CELU ) shares lost ~2% pre-market Monday after Morgan Stanley downgraded the cell therapy developer to Underweight from Equal Weight, citing the company’s recent strategic update. The analyst Jeffrey Hung notes that after a strategic review of its 2...

CELU - Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celul...
Previous 10 Next 10